Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › firsocostat

firsocostat

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of firsocostat

3 trials tracked of firsocostat.

3Trials tracked
0Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 2 2 Phase 1 1
  1. Phase 2 Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Participants With Nonalcoholic Steatohepatitis (NASH) Completed
  2. Phase 2 Study to Evaluate Safety, Tolerability, and Efficacy of GS-0976 in Adults With Nonalcoholic Steatohepatitis Completed
  3. Phase 1 Study to Evaluate the Pharmacokinetics of Firsocostat or Fenofibrate in Adults With Normal and Impaired Hepatic Function Completed

Showing the 3 most-cited and recently-updated of 3 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Efruxifermin shows superior fibrosis regression in compensated MASH cirrhosis compared to placebo in a network meta-analysis
Gastroenterology Meta-analysis
Efruxifermin shows superior fibrosis regression in compensated MASH cirrhosis compared to placebo in a network meta-analysis New drug ranking shows one treatment stands out for advanced fatty liver scarring
This network meta-analysis evaluated histological efficacy in patients with biopsy-proven compensated metabolic dysfunction-associated steat…
Efruxifermin is the only drug proven to shrink advanced liver scarring without worsening the disease, ranking first among new treatments for…
Apr 9, 2026